Improvement of quality of life in panic disorder with escitalopram, citalopram, or placebo

Pharmacopsychiatry

Volumn 40, Issue 4, 2007, Pages 152-156

  Bandelow, B ^a   Stein, D J ^b,e   Dolberg, O T ^c   Andersen, H F ^c   Baldwin, D S ^d  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c H LUNDBECK A S   (Denmark)

^d UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; ESCITALOPRAM; PLACEBO;

AGORAPHOBIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PANIC; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; TREATMENT OUTCOME;

CITALOPRAM; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; PANIC DISORDER; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUESTIONNAIRES; SEROTONIN UPTAKE INHIBITORS;

EID: 34548731282     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-984398     Document Type: Article

References (34)

1. APA. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders Fourth Edition Washington DC: American Psychiatric Press, 1994
2. Auquier P, Robitail S, Llorca PM, Rive B. Comparison of escitalopram and citalopram efficacy: A meta-analysis. International Journal of Psychiatry in Clinical Practice 2003; 7: 259-268
3. Baldwin DS, Anderson IM, Nutt DJ et al. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2005; 19: 567-596
4. Bandelow B. Panic and Agoraphobia Scale (PAS). Göttingen, Bern, Toronto, Seattle: Hogrefe & Huber Publishers, 1999
5. Bandelow B. Epidemiology of Depression and Anxiety. In: Kasper S, den Boer JA, Sitsen AJM (editors) Handbook on Depression and Anxiety. New York, NY: M. Dekker, 2003; 49-68
6. Bandelow B, Amering M, Benkert O et al. Cardio-respiratory and other symptom clusters in panic disorder. Anxiety 1996; 2: 99-101
7. Bandelow B, Andersen HF, Dolberg OT. Escitalopram in the treatment of anxiety symptoms associated with depression. Depress Anxiety 2007; 24: 53-61
8. Bandelow B, Broocks A, Pekrun G et al. The use of the Panic and Agoraphobia Scale (P&A) in a controlled clinical trial. Pharmacopsychiatry 2000; 33: 174-181
9. Bandelow B, Baldwin DS, Dolberg OT, Andersen HF, Stein DJ. What is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder, and generalized anxiety disorder? J Clin Psychiatry 2006; 67: 1428-1434
10. Bandelow B, Hajak G, Holzrichter S, Kunert HJ, Rüther E. Assessing the efficacy of treatments for panic disorder and agoraphobia. I. Methodological problems. Int Clin Psychopharmacol 1995; 10: 83-93
11. Bandelow B, Zohar J, Hollander E, Kasper S, Möller HJ. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders. World J Biol Psychiatry 2002; 3: 171-199
12. Bech P, Andersen HF, Wade A. Effective dose of escitalopram in moderate versus severe DSM-IV major depression. Pharmacopsychiatry 2006; 39: 128-134
13. Boulenger JP, Huusom AKT, Florea I, Baekdal T, Sarchiapone M. A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severe major depression. Curr Opin Med Res 2006; 22: 1331-1341
14. Candilis PJ, MacLean RY, Otto MW et al. Quality of life in patients with panic disorder. J Nerv Ment Dis 1999; 187: 429-434
15. Diamond R, Becker M. The Wisconsin Quality of Life Index: a multidimensional model for measuring quality of life. J Clin Psychiatry 1999; 60 (Suppl 3): 29-31
16. EMEA. European Medianes Agency. Committee for Medicinal Products for Human Use (CHMP). Guideline on Clinical Investigation of Medicinal Products Indicated for the Treatment of Panic Disorder. http://www.emea.europa.eu/pdfs/ human/ewp/428002en.pdf. Last accessed 3 May, 2007
17. Endicott J, Nee J, Harrison W, Blumenthal R. Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull 1993; 29: 321-326
18. Frisch MB, Clark MP, Rouse SV et al. Predictive and treatment validity of life satisfaction and the quality of life inventory. Assessment 2005; 12: 66-78
19. Gorman JM, Korotzer A, Su G. Efficacy comparison of escitalopram and citalopram in the treatment of major depressive disorder: pooled analysis of placebo-controlled trials. CNS Spectr 2002; 7: 40-44
20. Guy W. Clinical Global Impression Scale (CGI). ECDEU Assessment Manual for Psychopharmacology. In. Washington, DC: National Institute of Mental Health-US Dept of Health, Education, and Welfare publication (ADM), 1976;76-338
21. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959; 32: 50-55
22. Lam RW, Andersen HF. The influence of baseline severity on efficacy of escitalopram and citalopram in the treatment of major depressive disorder: an extended analysis. Pharmacopsychiatry 2006; 39: 180-184
23. Leucht S, Kane JM, Etschel E, Kissling W, Hamann JRR. Linking the PANSS, BPRS, and CGI: clinical implications. Neuropsychopharmacology 2006; 31: 2318-2325
24. Lochner C, Mogotsi M, Toit PL du et al. Quality of life in anxiety disorders: a comparison of obsessive-compulsive disorder, social anxiety disorder, and panic disorder. Psychopathology 2003; 36: 255-262
25. Mendlowicz MV, Stein MB. Quality of life in individuals with anxiety disorders. Am J Psychiatry 2000; 157: 669-682
26. Moore N, Verdoux H, Fantino B. Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder. Int Clin Psychopharmacol 2005; 20: 131-137
27. Quilty LC, Ameringen M Van, Mancini C, Oakman J, Farvolden P. Quality of life and the anxiety disorders. J Anxiety Disord 2003; 17: 405-426
28. Rapaport MH, Clary C, Fayyad R, Endicott J. Quality-of-life impairment in depressive and anxiety disorders. Am J Psychiatry 2005; 162: 1171-1178
29. Rapaport MH, Pollack M, Wolkow R, Mardekian J, Clary C. Is placebo response the same as drug response in panic disorder? Am J Psychiatry 2000; 157: 1014-1016
30. Sanchez C, Bogeso KP, Ebert B, Reines EH, Braestrup C. Escitalopram versus Citalopram: the surprising role of the R-enantiomer. Psychopharmacology (Berl) 2004; 174: 163-176
31. Shear MK, Brown TA, Barlow DH et al. Multicenter collaborative panic disorder severity scale. Am J Psychiatry 1997; 154: 1571-1575
32. Simon NM, Otto MW, Korbly NB et al. Quality of life in social anxiety disorder compared with panic disorder and the general population. Psychiatr Serv 2002; 53: 714-718
33. Stahl SM, Gergel I, Li D. Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2003; 64: 1322-1327
34. Stewart AL, Hays RD, Ware Jr JE. The MOS short-form general health survey. Reliability and validity in a patient population. Medical care 1988; 26: 724-735